Integrase inhibitor - PowerPoint PPT Presentation

The HIV Prevention Pipeline: A Future of Possibilities

The HIV Prevention Pipeline: A Future of Possibilities . IRMA Webinar August 23, 2012. Jim A. Turpin, Ph. D. Branch Chief Preclinical Microbicide and Prevention Research Branch Prevention Science Program Division of AIDS, NIAID , NIH. DHHS/NIH Required Disclaimer.

★ ★ ★ ★ ★

497 views • 36 slides

HIV that Is Resistant to Dolutegravir May not be Transmissible

HIV that Is Resistant to Dolutegravir May not be Transmissible. Mark A Wainberg McGill University AIDS Centre Jewish General Hospital. Disclosures. I have received honoraria from AbbVie, Bristol Myers Squib, Gilead, Janssen,Merck, ViiV. FLAMINGO (ING114915) Study Design.

★ ★ ★ ★ ★

683 views • 36 slides

July 24, 2012

Phase 1/2, Multicenter, Open-label, Pharmacokinetic, Safety, Tolerability, and Antiviral Activity Study of Dolutegravir (DTG), a Novel Integrase Inhibitor, in Combination Regimens in HIV-1 Infected Infants, Children, and Adolescents: P1093. July 24, 2012.

★ ★ ★ ★ ★

235 views • 15 slides

View Integrase inhibitor PowerPoint (PPT) presentations online in SlideServe. SlideServe has a very huge collection of Integrase inhibitor PowerPoint presentations. You can view or download Integrase inhibitor presentations for your school assignment or business presentation. Browse for the presentations on every topic that you want.